Open-label phase I clinical trial of Ad5-EBOV in Africans in China

Open-label phase I clinical trial of Ad5-EBOV in Africans in China

Background: To determine the safety and immunogenicity of a novel recombinant adenovirus type 5 vector based Ebola virus disease vaccine (Ad5-EBOV) in Africans in China. Methods: A phase 1, dose-escalation, open-label trial was conducted. 61 healthy Africans were sequentially enrolled, with 31 parti...

Full description

Bibliographic Details
Main Authors: Lihua Wu, Zhe Zhang, Hainv Gao, Yuhua Li, Lihua Hou, Hangping Yao, Shipo Wu, Jian Liu, Ling Wang, You Zhai, Huilin Ou, Meihua Lin, Xiaoxin Wu, Jingjing Liu, Guanjing Lang, Qian Xin, Guolan Wu, Li Luo, Pei Liu, Jianzhong Shentu, Nanping Wu, Jifang Sheng, Yunqing Qiu, Wei Chen, Lanjuan Li
Format: Article
Language:English
Published: Taylor & Francis Group 2017-09-01
Series:Human Vaccines & Immunotherapeutics
Subjects:
ad5-ebov
gp antibody
immunogenicity
safety
t-cell response
Online Access:http://dx.doi.org/10.1080/21645515.2017.1342021

Internet

http://dx.doi.org/10.1080/21645515.2017.1342021

Similar Items